Results of Phase 3 Ublituximab Trials Published, Showing Benefit in Relapsing MS
August 30, 2022
August 30, 2022
NEW YORK, Aug. 30 (TNSres) -- The National Multiple Sclerosis Society issued the following news:
Ublituximab (an experimental therapy being developed by TG Therapeutics) reduced relapses and disease activity on MRI scans significantly more than Aubagio(R) (teriflunomide, Sanofi Genzyme) in two phase 3 clinical trials. These results, originally reported at a medical meeting in 2021, have now been peer-reviewed and published in The New England Journal of Medicine. According to an Augu . . .
Ublituximab (an experimental therapy being developed by TG Therapeutics) reduced relapses and disease activity on MRI scans significantly more than Aubagio(R) (teriflunomide, Sanofi Genzyme) in two phase 3 clinical trials. These results, originally reported at a medical meeting in 2021, have now been peer-reviewed and published in The New England Journal of Medicine. According to an Augu . . .